SECTION 1. Chapter 175 of the General Laws, as appearing in the 2020 Official Edition, is hereby amended by inserting the following section:-
Section 47UU. (a) For the purposes of this section, the following terms shall have the following meanings unless the context clearly requires otherwise:
“Diabetic products”, prescription medications, diabetic testing supplies, and medical equipment necessary for treating diabetes.
“Smart InPens”, are all reusable insulin pens for the treatment of both Type 1 and Type 2 diabetes, which may include additional features, such as Bluetooth technology.
(b) Health insurance providers shall ensure that diabetic products adhere to the following price standards: (1) The general price of diabetic testing strips shall not exceed $10 per monthly supply of test strips. (2) The general price of diabetic lancets shall not exceed $10 per monthly supply of lancets. (3) The general price of diabetic pen needles and syringes shall not exceed $10 per monthly supply of pen needles and syringes. (4) The general price of insulin pumps and delivery systems shall not exceed $100 per pump. (5) The general price of a monthly supply of infusion sets for delivery systems shall not exceed $10 per month. (6) The general price of insulin cartridges for delivery devices shall not exceed $10 per month. (7) The general price of CGM transmitters shall not exceed $20 per transmitter. (8) The general price of a monthly supply of CGM sensors shall not exceed $20 per monthly supply. (9) The general price of insulin pens or vials shall not exceed $15 per month for vials or pens necessary for the treatment of patients. (10) The general price of blood glucose meters and monitoring systems shall not exceed $20 per system. (11) The general price of oral diabetes medication shall not exceed $10 per monthly supply of medication. (12) The general price of diabetic stem cell therapies shall not exceed $100 per session. (13) The general price of Smart InPens shall not exceed $20 per InPen. (14) If a patient requires three or more discrete diabetic medications, testing supplies, or equipment, the patient shall not be required to pay more than $100 a month for costs related to diabetes treatment.
(c) Nothing in this section shall be construed to limit the requirements for MassHealth to provide additional coverage for diabetic medication and healthcare-related products.
SECTION 2. Section 1 of this act shall take effect on January 1, 2024.
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.